Close Menu

NEW YORK – KeyGene said today that it has extended a worldwide, non-exclusive license agreement that grants Guardant Health the right to implement certain, undisclosed, next-generation sequencing technologies for which KeyGene holds patents.

The statement comes after another announcement on April 7 that the firm had also extended an existing worldwide non-exclusive license granted to LGC Biosearch Technologies for the commercial offering and use of KeyGene's patented SBG (Sequence-Based Genotyping) technology across agricultural and life sciences applications.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.